Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma

Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432

(2012) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study

(2011) Ticiana B. Leal et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Effect of Cytochrome P450 3A4 Inducers on the Pharmacokinetic, Pharmacodynamic and Safety Profiles of Bortezomib in Patients with Multiple Myeloma or Non-Hodgkinʼs Lymphoma

(2011) Andrzej Hellmann et al.   CLINICAL PHARMACOKINETICS

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

(2011) Philippe Moreau et al.   LANCET ONCOLOGY

Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: A prospective, multicenter, open-label, randomized, two-way crossover drug—drug interaction study

(2010) Karthik Venkatakrishnan et al.   CLINICAL THERAPEUTICS

Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkinʼs Lymphoma or Multiple Myeloma

(2009) David I. Quinn et al.   CLINICAL PHARMACOKINETICS

Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma

(2008) P. Moreau et al.   HAEMATOLOGICA